Rocket


Overview
Financials
News + Filings
Key Docs
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Odyssey Health, Inc. (ODYY) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Resignation/termination of a director
10/05/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ASSET PURCHASE AGREEMENT",
"Oragenics to Acquire Odyssey Health’ s Neurological Drug Technology Pipeline Including Concussion Drug Candidate"
08/18/2023 8-K Quarterly results
07/28/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/07/2023 8-K Quarterly results
06/28/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Speranza Therapeutics announces letter of intent to merge with public company, Odyssey Health Inc. BOCA RATON, Fla. June 28, 2023 Speranza Therapeutics, Inc. , a medical technology company dedicated to providing better patient outcomes by addressing large, underserved markets, and Odyssey Health Inc or , a publicly traded medical device company, have executed a non- binding letter of intent to merge."
04/04/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDMENT #5 TO CONVERTIBLE PROMISSORY NOTE",
"AMENDMENT #5 TO PROMISSORY NOTE"
03/17/2023 10-Q Quarterly Report for the period ended January 31, 2023
01/13/2023 4 RICHARDSON RICKY (Director) has filed a Form 4 on Odyssey Health, Inc.
Txns: Granted 500,000 options to buy @ $0.3, valued at $150k
01/13/2023 4 REDMOND J MICHAEL (President & CEO) has filed a Form 4 on Odyssey Health, Inc.
Txns: Granted 100,000 options to buy @ $0.3, valued at $30k
Granted 400,000 options to buy @ $0.3, valued at $120k
01/13/2023 4 GANDOLFO JOHN P (Director) has filed a Form 4 on Odyssey Health, Inc.
Txns: Granted 500,000 options to buy @ $0.3, valued at $150k
01/13/2023 4 FARRELL CHRISTINE (CFO) has filed a Form 4 on Odyssey Health, Inc.
Txns: Granted 100,000 options to buy @ $0.3, valued at $30k
Granted 400,000 options to buy @ $0.3, valued at $120k
01/13/2023 4 Casey Jerome H (Director) has filed a Form 4 on Odyssey Health, Inc.
Txns: Granted 500,000 options to buy @ $0.3, valued at $150k
01/13/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
01/06/2023 8-K Resignation/termination of a director
01/03/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDMENT #4 TO CONVERTIBLE PROMISSORY NOTE",
"FORM OF AMENDMENT #4 TO PROMISSORY NOTE",
"AMENDMENT #1 TO PROMISSORY NOTE"
12/14/2022 10-Q Quarterly Report for the period ended October 31, 2022
11/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/25/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/23/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/23/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
11/23/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/23/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
11/18/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/04/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
10/31/2022 10-K Annual Report for the period ended July 31, 2022
10/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/03/2022 8-K Quarterly results
09/30/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program Las Vegas Nevada, Sept. 30, 2022 Odyssey Health, Inc. , f/k/a Odyssey Group International, Inc., a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board. The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a condition that currently has no FDA approved treatment. We have recently completed a Phase I human trial where our drug was proven to be safe and well tolerated. We are excited about the potential of initiating a Phase II trial to determine the e..."
09/30/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy